The HIFα-Stabilizing Drug Roxadustat Increases the Number of Renal Epo-Producing Sca-1⁺ Cells

Inhibition of the prolyl-4-hydroxylase domain (PHD) enzymes, leading to the stabilization of hypoxia-inducible factor (HIF) α as well as to the stimulation of erythropoietin (Epo) synthesis, is the functional mechanism of the new anti-anemia drug roxadustat. Little is known about the effects of roxa...

Full description

Bibliographic Details

Published in:	Cells
Main Authors:	Aline Jatho, Anke Zieseniss, Katja Brechtel-Curth, Jia Guo, Kai Oliver Böker, Gabriela Salinas, Roland H. Wenger, Dörthe M. Katschinski
Format:	Article
Language:	English
Published:	MDPI AG 2022-02-01
Subjects:	HIFα-stabilizing drugs PHD inhibitor roxadustat erythropoietin Sca-1
Online Access:	https://www.mdpi.com/2073-4409/11/4/753